Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies

Current Psychiatry Reports

Volumn 16, Issue 9, 2014, Pages

  Borisovskaya, Anna ^a   Pascualy, Marcella ^a   Borson, Soo ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Agitation; Alzheimer s disease; Caregiver support; Cognitive enhancers; Cognitive interventions; Cooperative dementia care; Neuropsychiatric symptoms

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; PRAZOSIN; PROPRANOLOL; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; BEDTIME DOSAGE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CAREGIVER BURDEN; CAREGIVER SUPPORT; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COGNITIVE THERAPY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; HEALTH CARE ACCESS; HUMAN; MENTAL DISEASE; MUSIC THERAPY; NAUSEA; NERVE STIMULATION; NEUROPROTECTION; NEUROPSYCHIATRIC IMPAIRMENT; NUTRITION; PROGNOSIS; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING; COGNITION DISORDERS; KINESIOTHERAPY; MENTAL DISORDERS; PROCEDURES; PSYCHOLOGY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOPAMINE AGENTS; EXERCISE THERAPY; HUMANS; MENTAL DISORDERS; NEUROPROTECTIVE AGENTS; PSYCHOTHERAPY;

EID: 84914815546     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0470-z     Document Type: Review

References (92)

1. Alzheimer’s Association. Alzheimer’s Association Report: 2013 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2013;9:208-245.
2. Reitz C, Mayeux R. Alzheimer’s disease: epidemiology, diagnostic criteria, risk factors, and biomarkers. Biochem Pharmacol. 2014;88:640–51.
3. Galimberti D, Scarpini E. Progress in Alzheimer’s disease research in the last year. J Neurol. 2013;260:1936–41.
4. DeFina PA, Moser RS, Glenn M, et al. Alzheimer’s Disease clinical and research update for health care practitioners. J Aging Res. 2013;2013:207178. doi:10.1155/2013/207178.
5. Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review. J Alzheimer’s Dis. 2014;41:615–31.
6. Hernandez RK, Farwell D, Kantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc. 2009;57:1997–2003.
7. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36:375–99.
8. Pepeu G, Giovanni MG, Braco L. Effect of cholinesterase inhibitors on attention. Chem Biol Interact. 2013;203:361–4.
9. Ferris SH, Farlow M. Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging. 2013;8:1007–14.
10. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer disease. Neurotox Res. 2013;24:358–69.
11. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9:338–45. An excellent summary of the duration and degree of benefit provided by the antidementia drugs and recommendations on their use as monotherapy and in combination.
12. Di Santo SG, Prinelli F, Adorni F, et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to the severity of Alzheimer’s disease. J Alzheimer’s Dis. 2013;35:349–61.
13. Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol. 2011;11:57–65.
14. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2:e000917. doi:10.1136/bmjopen-2012-000917.
15. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9:326–31.
16. Shah R. The role of nutrition and diet in Alzheimer disease: a systematic review. J Am Med Dir Assoc. 2013;14:398–402. A wonderful summary of current evidence regarding the impact of nutritional supplements and dietary modifications on cognitive decline in AD.
17. Forbes D, Thiessen EJ, Blake CM, et al. Exercise programs for people with dementia (Review). Cochrane Database Syst Rev. 2013;12, CD006489. A much-needed plain-language summary of the potential benefits of exercise in dementia, an update on the Cochrane review from 2008.
18. Pitkälä K, Savikko N, Poysti M, et al. Efficacy of physical exercise intervention on mobility and physical functioning in older people with dementia: a systematic review. Exp Gerontol. 2013;48:85–93.
19. Blankevoort CG, Van Heuvelen MJG, Boersma F, et al. Review of effects of physical activity on strength, balance, mobility and ADL performance in elderly subjects with dementia. Dement Geriatr Cogn Disord. 2010;30:392–402.
20. Alves J, Magalhaes R, Thomas RE, et al. Is there evidence for cognitive intervention in Alzheimer disease? A systematic review of efficacy, feasibility, and cost-effectiveness. Alzheimer Dis Assoc Disord. 2013;27:195–203. A very selective review of only high-quality RCTs of cognitive interventions in AD, calling for further much-needed well-designed research in this area.
21. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer’s or vascular ype: a review. Alzheimer’s Res Ther. 2013;5:35.
22. Shecker M, Pirnay-Dummer P, Schmidtke K, et al. Cognitive Interventions in mild Alzheimer’s Disease: a therapy-evaluation study on the interaction of medication and cognitive treatment. Dement Geriatr Cogn Disord. 2013;3:301–11.
23. Kannan SF, McDowd JM, Colgrove Y, et al. Feasibility and efficacy of intensive cognitive training in early-stage Alzheimer’s disease. Am J Alzheimers Dis Other Dement. 2014;29:150–8.
24. Ballard C, Khan Z, Clack H, Corbett A. Non-pharmacologic treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):589–95.
25. Buschert V, Bokde ALW, Hampel H. Cognitive intervention in Alzheimer disease. Nat Rev Neurol. 2010;6:508–17.
26. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr. 2010;22(3):346–72. An excellent review of treatment of neuropsychiatric symptoms in AD.
27. Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–81.
28. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;277(10):806–12.
29. A. P. A. Work Group on Alzheimer's disease and other dementias, Rabins PV, Blacker D, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12 Suppl):5–56.
30. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006;14(7):561–72.
31. Ballard CG, Margallo-Lana M, Fossey J, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry. 2001;62(8):631–6.
32. American Psychiatric Association and American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association. xliv; 2013. p. 947. xliv, 947 p.
33. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc. 1994;42(11):1160–6.
34. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9(4):361–81.
35. Sloane PD, Hoeffer B, Mitchell CM, et al. Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: a randomized, controlled trial. J Am Geriatr Soc. 2004;52:1795–804.
36. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20(5):459–64.
37. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5):813–24.
38. Grossberg GT, Pejovic V, Miller ML, et al. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;27(2):164–72.
39. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60(2):107–15.
40. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968–76.
41. Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(7):537–50.
42. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007;4(1):81–93.
43. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525–38.
44. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.
45. Kamble P, Chen H, Sherer JT, et al. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging. 2009;26(6):483–92.
46. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA. 2014;311(7):682–91. An important RCT of citalopram for agitation in dementia associated with AD.
47. Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19(1):23–8.
48. Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744–51.
49. Ujkaj M, Davidoff DA, Seiner SJ, et al. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry. 2012;20:61–72. The largest examination of ECT for agitation in demented patients.
50. Starkstein SE, Chemerinski E, Sabe L, et al. Prospective longitudinal study of depression and anosognosia in Alzheimer's disease. Br J Psychiatry. 1997;171:47–52.
51. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7.
52. Teng E, Ringman JM, Ross LK, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008;16(6):469–77.
53. Van der Mussele S, Bekelaar K, Le Bastard N, et al. Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. Int J Geriatr Psychiatry. 2013;28(9):947–58.
54. Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. Neurology. 1998;51(1 Suppl 1):S53–60. discussion S5-7.
55. Garcia-Alberca JM, Lara JP, et al. Sleep disturbances in Alzheimer's disease are associated with neuropsychiatric symptoms and antidementia treatment. J Nerv Ment Dis. 2013;201(3):251–7.
56. Porta-Etessam J, Tobaruela-Gonzalez JL, Rabes-Berendes C. Depression in patients with moderate Alzheimer disease: a prospective observational cohort study. Alzheimer Dis Assoc Disord. 2011;25(4):317–25.
57. Seyfried LS, Kales HC, Ignacio RV, et al. Predictors of suicide in patients with dementia. Alzheimers Dement. 2011;7(6):567–73.
58. Kritz-Silverstein D, Barrett-Connor E, Corbeau C. Cross-sectional and prospective study of exercise and depressed mood in the elderly: the Rancho Bernardo study. Am J Epidemiol. 2001;153(6):596–603.
59. Vital TM, Hernandez SS, Stein AM, et al. Depressive symptoms and level of physical activity in patients with Alzheimer's disease. Geriatr Gerontol Int. 2012;12(4):637–42.
60. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003;290(15):2015–22.
61. Sturmey P. Behavioral activation is an evidence-based treatment for depression. Behav Modif. 2009;33(6):818–29.
62. Regan B, Varanelli L. Adjustment, depression, and anxiety in mild cognitive impairment and early dementia: a systematic review of psychological intervention studies. Int Psychogeriatr. 2013;25(12):1963–84.
63. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577–85.
64. Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136–45.
65. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18(4):332–40.
66. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–11. A recent well-designed trial of antidepressants for treatment of depression in dementia, with negative results.
67. Echavarri C, Burgmans S, Uylings H, et al. Neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013;33(3):715–21.
68. Teri L, Ferretti LE, Gibbons LE, et al. Anxiety of Alzheimer's disease: prevalence, and comorbidity. J Gerontol A Biol Sci Med Sci. 1999;54(7):M348–52.
69. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001;13(2):233–40.
70. Starkstein SE, Jorge R, Petracca G, et al. The construct of generalized anxiety disorder in Alzheimer disease. Am J Geriatr Psychiatry. 2007;15(1):42–9.
71. Ferretti L, McCurry SM, Logsdon R, et al. Anxiety and Alzheimer's disease. J Geriatr Psychiatry Neurol. 2001;14(1):52–8.
72. Hynninen MJ, Breitve MH, Rongve A, et al. The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. Int Psychogeriatr. 2012;24(11):1771–8.
73. Gibbons L, Teri L, Logsdon R, et al. Anxiety symptoms as predictors of nursing home placement in patients with Alzheimer's disease. J Clin Geropsych. 2002;8(4):335–42.
74. Paukert AL, Calleo J, Kraus-Schuman C, et al. Peaceful Mind: an open trial of cognitive-behavioral therapy for anxiety in persons with dementia. Int Psychogeriatr. 2010;22(6):1012–21.
75. Qazi A, Spector A, Orrell M. User, carer and staff perspectives on anxiety in dementia: a qualitative study. J Affect Disord. 2010;125(1–3):295–300.
76. Gardner ME, Malone DC, Sey M, et al. Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. J Am Med Dir Assoc. 2004;5(2):101–6.
77. Savaskan E, Schnitzler C, Schroder C, et al. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol. 2006;9(5):507–16.
78. Cooper JP. Buspirone for anxiety and agitation in dementia. J Psychiatry Neurosci. 2003;28(6):469.
79. Beinart N, Weinman J, Wade D, Brady R. Caregiver burden and psychoeducational interventions in Alzheimer’s disease: a review. Dement Geriatr Cogn Dis Extra. 2012;2:638–48.
80. US Department of Health and Human Services. National plan to address Alzheimer’s disease: 2014 update.
81. Levy K, Lanctot KL, Farber SB, et al. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease relieve caregiver burden? Drugs Aging. 2012;29(3):167–79.
82. Vann AS. A caregiver’s wish list for a national Alzheimer’s agenda. Am J Alzheimers Dis Other Dement. 2014;29(2):111–3. A wish list from a caregiver – an important perspective for anyone involved in the treatment of patients with dementia.
83. Zabalegui A, Hamers JPH, Karlsson S, et al. Best practices interventions to improve quality of care of people with dementia living at home. Patient Educ Couns. 2014;95:175–84.
84. Bass DM, Judge KS, Snow AL, et al. Caregiver outcomes of Partners in Dementia Care: effect of a care coordination program for veterans with dementia and their family members and friends. J Am Geriatr Soc. 2013;61:1377–86. Description of a model program meant to enhance care provision for patients with AD and their caregivers.
85. Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med. 2006;145:713–26.
86. Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;295:2148–57.
87. Passoni S, Moroni L, Toraldo A, et al. Cognitive behavioral group intervention for Alzheimer caregivers. Alzheimer Dis Assoc Disord. 2014. doi:10.1097/WAD.0000000000000033.
88. Godwin KM, Millis WL, Anderson JA. Kunik ME Technology-driven interventions for caregivers of persons with dementia: a systematic review. Am J Alzheimers Dis Other Dement. 2013;28:216–22.
89. Lines LM, Ahaghoute C, Tilly J, Wiener JM. Care coordination for people with Alzheimer’s disease and related dementias: literature review. US Department of Health and Human Services Assistant Secretary for Planning and Evaluation Office of Disability, Aging, and Long-Term Care Policy. December 2013.
90. Lessig M, Farrell J, Madhavan E, et al. Cooperative dementia care clinics: a new model for managing cognitively impaired patients. J Am Geriatr Soc. 2006;54:1937–42.
91. Borson S, Scanlan JM, Sadak T, et al. The Dementia Services Mini-Screen: a simple method to identify patients and caregivers needing enhanced dementia care services. Am J Geriatr Psychiatry. 2013. doi:10.1016/j.jagp.2013.11.001. (Epub ahead of print). A helpful guide to identify patients and caregivers who need higher level of services.
92. Borson S, Chodosh J. Developing dementia-capable health care systems: a 12-step program. Clin Geriatric Med: Update in Geriatric Psychiatry (in press).